University of Wollongong

Research Online
Graduate School of Medicine - Papers (Archive)

Faculty of Science, Medicine and Health

1-1-2011

Sound assessment of a role for fish oil in therapeutics or prevention of
cardiovascular disease jeopardised by confused study design
Peter L. McLennan
University of Wollongong, petermcl@uow.edu.au

Follow this and additional works at: https://ro.uow.edu.au/medpapers
Part of the Medicine and Health Sciences Commons

Citation
McLennan, Peter L., 2011, Sound assessment of a role for fish oil in therapeutics or prevention of
cardiovascular disease jeopardised by confused study design.
https://ro.uow.edu.au/medpapers/430

Research Online is the open access institutional repository for the University of Wollongong. For further information
contact the UOW Library: research-pubs@uow.edu.au

Sound assessment of a role for fish oil in therapeutics or prevention of
cardiovascular disease jeopardised by confused study design
Abstract
The study by Galan and colleagues in the SU.FOL.OM3 collaborative group has added further confusion to
the omega-3 story, which in this case largely derives from confusion in the study design. Confusion about
the likely mechanism of cardiovascular protection and hence expected outcomes; confusion in the
subject selection; confusion about the timing of intervention; confusion about the active components of
fish oil.
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The study by Galan and colleagues in the SU.FOL.OM3 collaborative
group has added further confusion to the omega-3 story, which in this case
largely derives from confusion in the study design. Confusion about the
likely mechanism of cardiovascular protection and hence expected outcomes;
confusion in the subject selection; confusion about the timing of
intervention; confusion about the active components of fish oil.
First: epidemiology emphasises reduced cardiovascular mortality with
fatty fish consumption, especially from sudden cardiac (arrhythmic) death
and heart failure. (1-4) Intervention trials that demonstrate reduced
mortality often do so without preventing new ischaemic events. (5-6) This
study population, by including acute coronary syndrome (ACS) and stroke in
addition to post-MI patients demonstrates the primary expectation of
ischaemia prevention and as a result includes less than 50% of subjects
with a clear arrhythmic substrate or heart failure predisposition. This
resulted in inclusion of mainly vascular primary endpoints including: nonfatal myocardial infarction; ischaemic stroke; death from fatal myocardial
infarction or stroke; and aortic dissection (ACS was a secondary
endpoint). What is the experimental evidence to suggest that fish oil can
modify these events at low intakes? In contrast, experimental evidence
suggests that the cardioprotective effects of fish oil are due primarily
to their influence on cardiac function, which is dependent on omega-3
polyunsaturated fatty acid (PUFA) incorporation into myocardial cell
membranes (7-8) producing intrinsic cardiac outcomes. (6,9) There can be
little expectation that the unstable angina and especially stroke patients
will have an arrhythmic episode or heart failure that might be prevented
by low dose omega-3 PUFA. Similarly, although ACS may be prevented by
regular fish intake, (10) and there is an experimental basis for altered
myocardial response to ischaemia and reperfusion by nutritional
preconditioning, (11-12) (not reduced incidence of ischaemia), the
likelihood of identifying a change in ACS is diluted by the >70% stroke
and post-MI patients in the study population.
Secondly: as noted by the authors, the mean interval between MI and
entry into the study was 101 days. In the GISSI-P study subjects were
recruited immediately post-MI (mean 16 days) and fatal arrhythmia
prevention occurred early, with a significant difference in arrhythmic
death evident by 120 days (close to the mean time of initial recruitment
for subjects in this study). (6,13)

Thirdly: the fish oil preparation contained omega-3 PUFA
predominantly as the fatty acid EPA. Considering the importance of omega3 PUFA incorporation into membranes to modify heart function and ischaemic
vulnerability, the principal omega-3 PUFA in the heart is undoubtedly
DHA,(14,15) and animal studies show that, when provided in the diet in low
doses, pure DHA is antiarrhythmic but pure EPA is not. (16) Similarly,
preferential effects of DHA have been reported in several human conditions
modified by fish oils. Although the omega-3 PUFA product used in the
GISSI studies had EPA>DHA, it provided 380 mg DHA daily, almost double
the dose used in this study. (6,9)
Fourthly: and not specific to this study, is the common
consideration of EPA and DHA as equivalent and interchangeable. It is
notable that the majority of food fish provide DHA in excess of EPA. (15)
This may be an important contributor to the negative outcomes of this and
other low-dose intervention studies which use high EPA oils (17) and which
may not provide sufficient DHA to reproduce the effects associated with
dietary habits in epidemiology.
Intervention trials such as this will likely continue to fail to
reproduce the promise of the epidemiology and experimental studies and
fail to translate them into clinical practice while they fail to reproduce
the conditions revealed by those studies. By consistently looking for
outcomes that are not supported by experimental evidence and biological
plausibility or predicted by epidemiology, and in failing to reproduce the
fatty acid intakes typical of dietary intake from fish, they are setting
themselves up to fail. Before the concept of fish oil intervention for
cardioprotection is rejected, it is important that some low-dose
intervention trials are instigated that use a DHA intake more consistent
with regular consumption of fish and address evidence-based biologically
plausible mechanisms using appropriate subject groups in each case.
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